Evidence map›Paper›PMID 40927124›Full record

ArticleCureus2025

Sudden-Onset Severe Thrombocytopenia Secondary to Trimethoprim-Sulfamethoxazole.

Jonathan Spadafora, Philip Spadafora, James Spadafora, Jonathan Starcke, Philip F Spadafora

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jonathan SpadaforaCollege of Osteopathic Medicine, New York Institute of Technology, Old Westbury, USA.
Philip SpadaforaCollege of Osteopathic Medicine, New York Institute of Technology, Old Westbury, USA.
James SpadaforaCollege of Osteopathic Medicine, New York Institute of Technology, Old Westbury, USA.
Jonathan StarckeCollege of Osteopathic Medicine, New York Institute of Technology, Old Westbury, USA.
Philip F SpadaforaInternal Medicine, NYU Langone Hospital - Long Island, Mineola, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced immune thrombocytopenia (DITP) is a rare but life-threatening condition characterized by a sudden and serious drop in the number of platelets from drug-dependent antibodies against platelet glycoproteins. We report the case of a 57-year-old man who developed severe thrombocytopenia and mucocutaneous bleeding following a short course of trimethoprim-sulfamethoxazole (TMP-SMX) for presumed tick-borne disease. The patient experienced bleeding gums, pinpoint rashes, bruising, and extreme fatigue. The laboratory tests indicated a severely low platelet count of 1 × 1.0 × 10³/µL combined with a high immature platelet fraction (IPF). Workup for both infection and autoimmune disorders would be negative, along with the absence of intracranial hemorrhage demonstrated on imaging. The timeline and clinical picture suggested that TMP-SMX was the most likely culprit. The patient was placed on supportive care, including platelet transfusion and re-start of doxycycline after discontinuation of the drug. His platelet count began to rise, and his symptoms improved; he was discharged without issues. By presenting this instance, we place high importance on early recognition and immediate withdrawal of the offending agent to prevent life-threatening bleeding. Though confirmatory testing of antibodies is available, clinical diagnosis remains the gold standard due to delays in testing and availability.

Indexed as

drug‑induced immune thrombocytopeniapetechiaeplatelet transfusionsudden-onset thrombocytopeniatmp‑smx (trimethoprim‑sulfamethoxazole)

Identifiers

PMID40927124
PMCPMC12416223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.